April 20, 2018 5:11 PM ET

Healthcare Equipment and Supplies

Company Overview of Arch Therapeutics, Inc.

Company Overview

Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

235 Walnut Street

Suite 6

Framingham, MA 01702

United States

Founded in 2006

8 Employees



Key Executives for Arch Therapeutics, Inc.

Co-Founder, President, CEO & Director
Age: 52
Total Annual Compensation: $447.5K
CFO, Principal Accounting Officer & Treasurer
Age: 59
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2017.

Arch Therapeutics, Inc. Key Developments

Arch Therapeutics, Inc. Presents at MicroCap Conference 2018, Apr-09-2018

Arch Therapeutics, Inc. Presents at MicroCap Conference 2018, Apr-09-2018 . Venue: JW Marriott Essex House, 160 Central Park South, New York, New York, United States.

Arch Therapeutics, Inc. Provides Update on 510(K)

Arch Therapeutics, Inc. announced that it has utilized the Food and Drug Administration’s pre-submission process to submit a proposed development strategy to the FDA to address the agency’s comments on its previous 510(k) submission for its AC5 Topical Gel product. The 510(k) package previously submitted by Arch included a comprehensive battery of tests. The agency requested further evidence that the product does not cause sensitization in humans. In order to provide a comprehensive response to the agency and minimize further delay, the company consulted with several medical experts and developed a strategy to perform a small, three-month long, non-invasive human study to provide the additional data to the FDA. The Company has presented this proposal to the FDA via the pre-submission process with the intention of ensuring that the strategy will address their questions.

Arch Therapeutics, Inc. Presents at 30th Annual ROTH Conference, Mar-12-2018 04:30 PM

Arch Therapeutics, Inc. Presents at 30th Annual ROTH Conference, Mar-12-2018 04:30 PM. Venue: The Ritz Carlton, Laguna Niguel in Orange County, 1 Ritz Carlton Dr., Dana Point, California, United States. Speakers: Terrence W. Norchi, Co-Founder, President, CEO & Director.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Arch Therapeutics, Inc., please visit www.archtherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.